The analyst is extremely bullish on the AI sector, recommending investors buy chip stocks like NVIDIA (NVDA) with a price target of $200. Following positive FDA news, Sarepta (SRPT) is seen as a strong buy on dips under $21, with a potential short-term price target in the high $20s. Cel-Sci (CELC) is also considered a buy due to promising drug data and an attractive valuation, while Abivax (ABVX) is highlighted as a high-conviction holding. Conversely, investors are strongly advised to avoid the hype around corporate Bitcoin (BTC) treasuries, which is viewed as a dangerous and speculative trend. Caution is also advised for UnitedHealth Group (UNH) due to risks of permanent restructuring.

Sarepta Therapeutics (SRPT)

• The speaker initially described Sarepta as a "painful shitty dog" and a "deep value" stock that has been "beaten to shit." This type of investment requires patience and the ability to withstand pain, as it can take years for them to recover.
• A major development occurred during the podcast: the FDA lifted its clinical hold on Sarepta's drug, Elevidys, concluding that a patient's death was unrelated to the drug.
• This news caused the stock to be unhalted and rally significantly. The speaker became very bullish following the news.
• Valuation Potential: The speaker believes the stock could go to $50, or even $90, based on a simple valuation model. He notes the drug was doing $2 billion in sales before the hold and could return to that level. A 3x revenue multiple on $3 billion in potential revenue would imply a $9 billion market cap, or $90 per share.
• Trading Strategy: The speaker suggests a potential trading strategy after the initial pop:
  • Buying under $20 or $21 is attractive.
  • He would consider selling or trimming the position around $25 to $30 to "book the win."

Takeaways

• Sentiment: Very Bullish following the FDA news.
• Catalyst: The FDA's decision to lift the clinical hold on Elevidys is a massive de-risking event for the company.
• Actionable Insight: The speaker sees significant upside potential from the post-halt price. For investors who bought at lower prices, this is a major win. For new investors, the speaker suggests buying on dips under $21 could be a good entry point, with a potential short-term exit target in the high $20s. This is a high-risk biotech stock, but the recent news has dramatically improved its outlook.

Cel-Sci Corporation (CELC)

• The stock was a massive gainer, up 250% at one point on news about its PI3K drug, Jedatolisib.
• The speaker notes the trial data was "extremely potent and impressive," with a hazard ratio of 0.24.
• He compares it favorably to Novartis's (NVS) drug Picray, another PI3K inhibitor. He believes CELC's drug looks "a lot better than Picray," which does about $500 million in sales.
• He suggests CELC's drug could do $1 billion in revenue.
• Despite the stock being "a little wobbly" after the initial spike, the speaker believes it is a buy. He notes the market cap is only $1.5 billion, which he considers "not bad" given the drug's potential.

Takeaways

• Sentiment: Bullish.
• Catalyst: Strong clinical trial data for its PI3K drug.
• Actionable Insight: The speaker believes that even after the massive price increase, the stock could be a good investment ("I think this is a buy"). He sees the potential for the drug to generate $1 billion in revenue, making the current $1.5 billion market cap seem attractive. Investors should be aware of the volatility that comes after such a large price move.

NVIDIA (NVDA) & The AI Sector

• The speaker is extremely bullish on the AI sector, stating "Chips rule everything around me."
• He has a price target for NVIDIA of $200.
• The bullish case is driven by massive, ongoing demand for computing power.
  • Anthropic was mentioned as being in deal talks where its valuation jumped from $100 billion to $150 billion due to intense competition among investors.
  • Prominent tech leaders like Sam Altman and Elon Musk are talking about needing 100x more compute and are buying every GPU they can.
• The speaker believes the AI trend is still in its early stages and capital is continuing to pour into the space. He dismisses the idea that individuals will run powerful AI models locally on their own computers due to the technical complexity and rapidly increasing computational requirements.

Takeaways

• Sentiment: Very Bullish.
• Key Trend: The demand for AI computing power is described as a massive, ongoing tailwind for chip companies.
• Actionable Insight: The speaker explicitly recommends buying chip stocks like NVIDIA, and even suggests AMD and Intel as part of the same theme. He has a specific price target of $200 for NVDA. This is a play on the entire AI ecosystem's infrastructure needs.

Bitcoin (BTC)

• The speaker expressed a very negative and skeptical view of companies adding Bitcoin to their corporate treasuries.
• He calls the trend "absurd" and a "very dangerous thing."
• He compares the current excitement to "SPAC fever... with cancer," suggesting it is a toxic trend that is "not going to end well."
• He questions the fundamental strength of Bitcoin, stating its "cryptography is very weak."
• While acknowledging Bitcoin is performing well now, he believes it could be seen as a "crazy delusion" in 10 years.

Takeaways

• Sentiment: Very Bearish.
• Risk Factor: The trend of companies raising money to buy Bitcoin is seen as a major market risk and a sign of speculative excess.
• Actionable Insight: The speaker strongly advises against getting caught up in the hype around corporate Bitcoin treasuries. He views it as a bubble-like activity with a high probability of a negative outcome, comparing it to the disastrous SPAC boom.

Cardiff Oncology (CRDF)

• The company has a binary event (likely clinical trial data) expected "tomorrow."
• The speaker is explicitly bearish on the outcome.
• He states, "I don't think Cardiff's going to make it" and "Cardiff's not going to work."
• He mentions he will "place a little bet," which implies taking a short position or buying put options to profit if the stock price falls on the news. He estimates there is a 90% chance it doesn't work.

Takeaways

• Sentiment: Very Bearish.
• Catalyst: An upcoming binary data release that the speaker expects to be negative.
• Actionable Insight: This is a high-risk, speculative trade idea. The speaker is betting against the company ahead of a major catalyst. This is an expert-level strategy and highly risky for the average investor.

Other Stock & Sector Mentions

• Palantir (PLTR): The speaker stated, "I would not be short, Palantir," indicating a neutral to bullish stance.
• Quantum Computing (D-Wave, IonQ, Rigetti): The speaker is skeptical about the sector's near-term prospects. He notes that hype needs to be replaced by actual revenue and numbers, and points out that D-Wave (QBTS) and IonQ (IONQ) were down on the day.
• Abivax (ABVX): The speaker holds a "really big position" in Abivax. He has high conviction due to what he believes is very strong data, stating he doesn't see how the stock can trade down.
• LVMH (LVMUY): Expressed positive sentiment, saying "I like LVMH. I always have."
• UnitedHealth Group (UNH): The speaker does not like the stock. While it may be undervalued, he is wary of the risk that the company may have to be "permanently restructured." He advises caution and suggests not rushing to buy it.
• International Themes: The speaker briefly mentioned an interest in:
  • Indonesian commodities and mining companies
  • European cement companies
  • Canadian and Indian life insurance companies